Top stories

View all news

Geneva, 10 June 2021 – Gavi, the Vaccine Alliance, today welcomes the decision by the United States Government to procure 500 million COVID-19 vaccine doses on behalf of the COVAX Facility.

Gavi, the Vaccine Alliance, welcomes the announcement by the United States Government of its strategy for global vaccine sharing, which sets out how it will provide at least 80 million doses of vaccines to the rest of the world – with the…

The Gavi COVAX AMC Summit “One World Protected” virtual event, hosted today by the Government of Japan and Gavi, the Vaccine Alliance, raised US$ 2.4 billion from nearly 40 donor governments, the private sector and foundations, exceeding the…

COVAX vaccine roll-out

>81 million COVAX vaccines shipped
OWP
129 participants

As of 8 June 2021

COVAX Facility

Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.

Learn more

The COVID-19 vaccine race

Pre-clinical
185vaccines
are being explored in lab experiments and animals
PHASE 1
35 vaccines
are undergoing safety tests in healthy young individuals
Phase 2
37vaccines
are being tested in broader groups of people
Phase 3
25vaccines
are in large international trials to test their impact on COVID-19
IN USE
15vaccines
are currently being offered to the general population
Phase 4
5vaccines
are being monitored in the wider population after being approved

Source: WHO

Learn more

COVID-19 vaccines

Accurate, evidence-based information about COVID-19 vaccines to provide people with essential facts about the vaccines that will help end this crisis.

Learn more

Accurate, evidence-based information about COVID-19 vaccines to provide people with essential facts about the vaccines that will help end this crisis.

Learn more

#VaccinesWork

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Top VaccinesWork stories

View all stories

We remain locked in a deadly race with the virus. We will only win when we have created a “variant-proof” world that can keep a lid on the havoc caused by its troublesome mutations.

Amid the 28.4 million cases and over 300 thousand deaths from SARS-CoV-2, a second epidemic has hit India. ‘Black fungus’, clinically known as mucormycosis, is an infection currently affecting nearly 12,000 immunocompromised patients recovering…

While we don't know exactly what causes it yet, there are a few theories put forward by a few researchers around the world.

Supported countries

Supported Countries

Our impact

Syringe >822 million children immunised
First aid locator >14 million future deaths prevented
Transitioned 16 countries transitioned from Gavi support
Billions >150 US$ billion in economic benefits for countries (2000–2017)
Children 85% of the world's children reached by routine immunisation

Our mission: save lives and protect people's health

Saving lives and protecting people’s health by increasing equitable and sustainable use of vaccines.

Learn more

Saving lives and protecting people’s health by increasing equitable and sustainable use of vaccines.

Learn more

Our partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Like. Follow. Share.

    Subscribe to our newsletter